Skip to main content
Fig. 3 | Journal of Translational Medicine

Fig. 3

From: Identification of a 4-lncRNA signature predicting prognosis of patients with non-small cell lung cancer: a multicenter study in China

Fig. 3

The 4-lncRNA signature predicted different survivals rates in patients with NSCLC at the same TNM stage. Based on the 4-lncRNA signature risk score, patients with NSCLC at the same stage were divided into high- and low-risk groups. Kaplan–Meier survival analysis was performed to estimate patients’ survival rate in the discovery cohort. NSCLC patients with high risk (based on the 4-lncRNA signature) showed significantly poorer OS (left panel) and DFS (right panel) rates than those in low-risk group at a stage I (n = 87), b stage II (n = 32) and c stage III (n = 84)

Back to article page